Viyash Scientific Ltd

Viyash Scientific Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Viyash Scientific Ltd

₹ 248 -0.78%
03 Jun - close price
sequent.in BSE: 512529 NSE: VIYASH
About

Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.

Key Points

Business segments
The company has 2 business segments: Formulation and API. [1]

Website BSE NSE
  • Market Cap ₹ 10,830 Cr.
  • Current Price ₹ 248
  • High / Low ₹ 277 / 166
  • Stock P/E 103
  • Book Value ₹ 73.0
  • Dividend Yield 0.00 %
  • ROCE 8.01 %
  • ROE 4.84 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 26.1% CAGR over last 5 years

Cons

  • Stock is trading at 3.40 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 2.85% over last 3 years.
  • Working capital days have increased from 64.8 days to 135 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
47 40 49 42 37 58 42 338 42 41 340 342 372
53 49 57 46 43 60 44 280 45 43 288 271 310
Operating Profit -6 -9 -8 -4 -6 -2 -2 58 -3 -2 52 70 63
OPM % -13% -22% -16% -10% -16% -3% -5% 17% -7% -5% 15% 21% 17%
8 3 10 13 13 11 12 13 12 10 16 -25 20
Interest 1 1 1 1 1 1 1 6 1 1 4 4 3
Depreciation 2 2 2 2 2 2 2 32 2 2 31 31 31
Profit before tax -1 -9 -1 6 4 6 6 34 6 5 33 11 49
Tax % 34% -25% -35% 25% 8% 26% 34% -52% 28% 30% 30% 101% 27%
-2 -7 -1 5 4 4 4 51 4 3 23 -0 36
EPS in Rs -0.07 -0.27 -0.04 0.18 0.15 0.18 0.17 2.04 0.17 0.13 0.91 -0.00 0.82
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
384 395 91 106 166 227 265 220 223 169 178 1,382
330 358 121 124 164 205 230 220 249 195 190 1,148
Operating Profit 54 36 -31 -18 3 22 35 -1 -26 -27 -11 235
OPM % 14% 9% -34% -17% 2% 10% 13% -0% -12% -16% -6% 17%
57 15 34 432 14 15 17 28 28 40 46 22
Interest 43 16 0 0 3 5 3 2 3 4 4 16
Depreciation 25 24 3 4 7 9 9 10 9 9 9 124
Profit before tax 43 10 -0 409 6 23 41 16 -10 -0 22 116
Tax % 4% 1% 0% 1% -22% 6% 21% 6% -38% -358% 28% 35%
41 10 -0 406 8 21 32 15 -6 1 16 76
EPS in Rs 2.71 0.44 -0.00 16.68 0.31 0.86 1.29 0.60 -0.24 0.02 0.63 1.74
Dividend Payout % 0% 0% 0% 1% 65% 0% 39% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 13%
5 Years: 39%
3 Years: 84%
TTM: 675%
Compounded Profit Growth
10 Years: 25%
5 Years: 26%
3 Years: 168%
TTM: 513%
Stock Price CAGR
10 Years: 7%
5 Years: -1%
3 Years: 50%
1 Year: 29%
Return on Equity
10 Years: 5%
5 Years: 2%
3 Years: 3%
Last Year: 5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 30 48 49 49 49 50 50 50 50 50 50 87
Reserves 126 1,158 1,209 900 868 837 980 991 1,008 1,037 1,093 3,102
341 49 87 0 44 35 6 17 20 47 46 33
153 94 106 29 57 76 67 66 44 54 34 433
Total Liabilities 650 1,348 1,450 977 1,019 997 1,102 1,124 1,123 1,188 1,222 3,655
201 170 188 24 52 69 66 67 57 43 46 1,162
CWIP 9 20 32 3 0 4 4 1 2 5 7 55
Investments 183 897 891 687 788 758 685 659 633 640 647 977
257 262 340 264 178 167 347 397 431 500 522 1,460
Total Assets 650 1,348 1,450 977 1,019 997 1,102 1,124 1,123 1,188 1,222 3,655

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-25 100 -24 -4 74 30 2 9 38 -27 -1 119
24 -359 -47 16 -114 -18 17 -4 -51 5 -0 -107
8 247 71 -12 40 -11 -21 7 0 22 1 -7
Net Cash Flow 7 -12 0 -0 0 2 -2 12 -13 1 -1 5
Free Cash Flow 58 76 -69 -12 71 25 -7 3 29 -12 -10 50
CFO/OP -44% 279% 74% 25% 2,774% 146% 54% -1,481% -146% 110% 39% 56%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 94 68 455 270 94 65 84 87 22 97 141 146
Inventory Days 126 94 315 64 98 101 154 228 129 117 87 171
Days Payable 132 123 352 113 203 208 197 193 99 126 79 182
Cash Conversion Cycle 88 39 417 221 -11 -41 41 122 53 88 148 136
Working Capital Days -202 115 541 333 12 -6 65 87 22 -5 64 135
ROCE % 24% 3% 0% 35% 1% 3% 5% 2% -1% 1% 2% 8%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2025
Number of Commercial APIs
Number

Log in to view insights

Please log in to see hidden values.

Login
Global Employee Headcount
Number
Global Presence (Countries Reached)
Number
Number of Finished Dosage Forms (FDFs)
Number
Number of Manufacturing Facilities
Number
R&D Expenditure
INR Million
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
52.79% 52.79% 52.79% 52.79% 52.78% 52.76% 52.61% 52.61% 52.61% 52.33% 61.41% 61.31%
6.27% 6.03% 6.12% 6.16% 5.69% 6.45% 6.10% 6.05% 6.15% 5.90% 3.16% 2.94%
2.92% 3.23% 7.23% 7.59% 8.06% 9.99% 12.01% 12.82% 12.98% 12.91% 7.36% 7.98%
37.64% 37.57% 33.69% 33.29% 33.30% 30.63% 29.12% 28.36% 28.10% 28.69% 27.97% 27.67%
0.39% 0.39% 0.17% 0.17% 0.17% 0.17% 0.16% 0.16% 0.16% 0.16% 0.09% 0.09%
No. of Shareholders 1,87,4741,84,5211,72,8531,66,5931,63,6931,54,6031,62,5741,58,1521,47,3201,44,0851,34,1941,27,446

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls